Companies › Lakefront Biotherapeutics West
1 active drug program in 2 registered trials: 2 Phase 1; Hematology, Immunology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| OM336 Bispecific antibody targeting BCMA and CD3 | BCMA, CD3 | Phase 1 | AIHA - Warm Autoimmune Hemolytic Anemia; Sjogrens Disease | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07083960 | OM336 | Phase 1 | AIHA - Warm Autoimmune Hemolytic Anemia | Hematology | Dec 2026 |
| NCT07229144 | OM336 | Phase 1 | Sjogrens Disease | Immunology | Jun 2027 |
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Kali Therapeutics Johnson & Johnson (Janssen) AstraZeneca iCell Gene Therapeutics AbbVie Chongqing Precision Biotech Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Excyte Biopharma Vironexis Biotherapeutics
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.